Pfizer has acquired Metsera for $4.9bn, because the drugmaker targets longer-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) to cement market share within the burgeoning weight reduction therapy sector.
Pfizer has agreed to purchase all of Metsera’s shares for a worth of $47.50 every, representing a 43% premium to Metsera’s closing share worth of $33.32 on 19 September. The deal, forecast to shut in This autumn 2025, additionally contains potential extra funds of as much as $22.50 per share in money tied to a few particular scientific and regulatory milestones from Metsera’s weight reduction drug portfolio.
Metsera’s inventory surged 36.6% to $52.59 on 22 September. Shares in Pfizer, which has a market cap of $139.5bn, rose by 1% at market open.
Metsera’s choices centre round injectable and oral peptides for weight reduction. The biotech has developed a platform that enables for much less frequent dosing – concentrating on administration on a month-to-month foundation. This is able to be a major enchancment on the weekly dosing seen with accredited weight reduction therapies.
On a convention name on 22 September, Pfizer’s chief scientific officer Chris Broshoff mentioned: “Buying a portfolio of scientific stage and pre-clinically potential best-in-class injectables with anticipated month-to-month, long-term dosing regimens will help our ambition to ship substantial worth to sufferers and to our shareholders.”
The acquisition marks a fast exit for Metsera, which was solely based in 2022 and publicly listed in January this yr through a $289m preliminary public providing (IPO).
The biotech at present has 4 programmes within the clinic. Its lead candidate is MET-097i, a weekly and month-to-month injectable GLP-1RA, each in Section II improvement (NCT06897202 and NCT06973720). Section IIa knowledge with MET-097i dosed on each a weekly and month-to-month routine have demonstrated strong weight reduction after 12 weeks, as per Pfizer.
MET-233i, a month-to-month amylin analogue candidate, is being evaluated in Section I trials as a monotherapy (NCT07022977) and together with MET-097i (NCT06924320).
The biotech additionally has two oral GLP-1RA candidates anticipated to start scientific trials imminently.
The contingent worth proper (CVR) included within the deal covers checkpoints for MET-097i and MET-233i. The scientific milestone is the Section III scientific trial begin of Metsera’s MET-097i+MET-233i mixture whereas regulatory milestones can be met if MET-097i, both as a monotherapy or together with MET-233i, positive aspects US Meals and Drug Administration (FDA) approval.
The deal catapults Pfizer onto the frontline of the following technology of weight problems therapies. The drugmaker’s weight reduction capsule hopeful, orforglipron, has demonstrated sturdy proof in scientific trials; nevertheless, Pfizer’s takeover of Metsera signifies a aim to distinguish its pipeline of therapies within the house dominated by Novo Nordisk and Eli Lilly. Each Novo and Lilly have been lively within the acquisition house this yr in efforts to consolidate weight problems therapy competitiveness.